Figure 2

(A) The immunohistochemical stain of different PD-L1 expression levels. (B) Progression-free survival among EGFR-mutant NSCLC patients receiving first-line EGFR-TKI. (C) Kaplan–Meier analysis of progression-free survival among patients with different PD-L1 expression levels.